OncLive | BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus OncLive Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels. In addition ... |
